The 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006
Oral Presentations
1 Relationship between use of stavudine and diabetes mellitus. S. de Wit, CA Sabin, R Weber, SW Worm, P Reiss, R Thiebaut, W El-Sadr, A D´Arminio Monforte, E Fontas, MG Law, AN Phillips, N Friis-Møller, JD Lundgren for the DAD study Group.
Slides as pdf file 60 kb>
2 Effect of interventions to improve dyslipidaemia. M de Valk, N Friis-Møller, CA Sabin, F Dabis, A d´Arminio Monforte, R Weber, S Worm, W El-Sadr, S de Wit, C Pradier, O Kirk, M Law, AN Phillips, JD Lundgren, P Reiss for the DAD study group
Slides as pdf file 96 kb
3 Final safety and efficacy analysis of a randomised pilot study evaluating early versus late switch from efavirenz to nevirapine as part of HAART: the BI Switch Study. M Youle, U B Dragsted, D Podlekareva, C Smith, A Caroll, F Turner, M Johnson
Poster Presentations
1 Comparison of single and boosted-protease-inhibitor (PI) versus non-nucleoside reverse transcriptase inhibitor (NNRTI) containing regimens in previously antiretroviral naïve patients. A Mocroft, O Kirk, A Horban, N CLumeck, HJ Stellbrink, A d´Arminio, K Zilmer, J Gatell, AN Phillips, JD Lundgren for the EuroSIDA study group.
Poster as pdf file 138 kb
2 Abacavir hypersensitivity reaction in EuroSIDA. W Bannister, N Friis-Møller, A Mocroft, JP Viard, J van Lunzen, O Kirk, P Garglianos, D Banhegyi, A Chiesi, J Lundgren for the EuroSIDA study group.
Poster as pdf file 673 kb
3 The Metabolic Syndrome at baseline in the D:A:D Study. S Worm, C Sabin, W El-Sadr, P Reiss, A Monforte, M Rickenbach, R Thiebaut, S de Wit, E Fontas, M Law, O Kirk, J Lundgren, N Friis-Møller for the DAD study
Poster as pdf file 129 kb
The XVI International AIDS Conference, Toronto, August 2006
Oral Presentations
1 Progression of HIV-related disease or death (POD) in the randomised SMART study:why was the risk of POD greater in the CD4 guided ((re)-initiate ART at CD4<250 cells/µL) drug conservation (DC) vs the virological suppression(VS) arm? Jens D. Lundgren on behalf of the SMART study group.
2 Risk of discontinuation of nevirapine due to toxicitites in antiretroviral naive and experienced patients with high and low CD4 counts. A Mocroft, J Rockstroh, J Gasiorowski, F Antunes, G Panos, A d´Arminio Monforte, A Rakhmanova,, AN Phillips, JD Lundgren for the EuroSIDA study group.
Slides as pdf file 153 KB
3 All naïve patients are not equal: when and how to start HAART. JD Lundgren
Link to session
Posters
1 The ability of four genotypic resistance algorithmis for predicting HIV-RNA responses 4-24 weeks after initiating a boosted PI-containing regimen. Z Fox, J Kjær, AN Phillips, L Ruiz, B Clotet, S Staszewski, C Holkmann Olsen, A Horban, B Ledergerber, JD Lundgren for the EuroSIDA study group.
Poster as pdf file 137 KB
2 Genotypic resistance profile before initiation of cART and association with virological and clinical outcome in EuroSIDA. WP Bannister, AN Phillips, B Clotet, P Reiss, B Ledergerber, A Lazzarin, C Katlama, A Cozzi-Lepri, L Ruiz, JD Lundgren for the EuroSIDA study group.
Poster as pdf file 85 KB
3 Short term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy: The EuroSIDA risk-score. A Mocroft, B Ledergerber, K Zilmer, O Kirk, B Hirschel, JP Viard, P Reiss, P Francioli, A Lazzarin, L Machala, AN Phillips, JD Lundgren for the EuroSIDA study and the Swiss HIV Cohort study.
Poster as pdf file 759 KB
4th European Drug Resistance Workshop, Monte Carlo, March 2006
1 The ability of four genotypic resistance algorithms to predict HIV-RNA responses to boosted PI-containing regimens after 4 and 12 weeks follow-up. Z Fox, M Gisslen, B Gazzard, J Kjær, H Nielsen, M Youle, I Cassetti, AN Phillips, UB Dragsted, and JD Lundgren on behalf of the MaxCmin1, MaxCmin2 and COLATE trial groups
Poster as pdf-file 636 KB
13th Conference on Retroviruses and Opportunistic Infections, Denver, February 2006
Oral presentation
1 Exposure to PI and NNRTI and risk of myocardial infaction: Results from the D:A:D Study. N Friis-Møller, P Reiss, W El-Sadr, A D´Arminio Monforte, R Thiebaut, S De Wit, R Weber, E Fontas, M Law, A Phillips, O Kirk, CA Sabin, JD Lundgren, and the D:A:D Study group
Posters
1 Mutation at reverse transcriptase codon 214 is antagonist to thymidine analogue mutations type 2 profiles and predicts virological response to thymidine analogue-containing cART regimens only if TAM type 1 profiles concomitantly detected. A Cozzi-Lepri, L Ruiz, F Ceccherini-Silberstein, A Mocroft, A Phillips, J Gatell, B Ledergerber, P Reiss, B Clotet, JD Lundgren and the EuroSIDA Study group.
Poster as pdf file 966 KB
2 Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4 cell counts in the EuroSIDA study. D Podlekareva, U Dragsted, A Mocroft, B Ledergerber, M Beniowski, A Lazzarin, J Weber, N Clumeck, A Phillips, JD Lundgren and the EuroSIDA Study group.
Poster as pdf file 76 KB
3 Exposure to antiretroviral therapy and the risk of liver-related death: Is there an association? Results from the D:A:D Study. R Weber, C Sabin, N Friis-Møller, A D'Arminio Monforte, P Reiss, W El-Sadr, F Dabis, M Law, C Pradier, S De Wit, O Kirk, A Phillips, JD. Lundgren; On behalf of the D:A:D Study Group
Poster as pdf file100 KB
Updated: 30 Oct 2007